Setting the “right” goal: post M&A innovation performance and goal orientation


Pharmaceutical firms spend billions of dollars to develop the next breakthrough drug and to maintain their market shares. We investigate how pharmaceutical firms use mergers and acquisitions to boost their innovation performance which has been found to result in better performance outcomes. Adding to the recent research on mergers and acquisitions, we found that firms that are explicit with their R&D goal orientation from the beginning of the acquisition journey are more successful in their innovation endeavours than firms with other goal orientation. Further, the firms’ prior acquisition experience appears to aid their innovation performance. However, we found that target size can affect the post-acquisition innovation performance but has diminishing returns as target size increases. Ultimately, our findings suggest that having an explicit R&D goal orientation is really important for a healthy innovation pipeline for pharmaceutical firms.

Keyword : mergers and acquisitions, innovation, R&D, goal orientation, acquisition experience, organizational learning, pharmaceutical industry

How to Cite
Doan, T. T. (2020). Setting the “right” goal: post M&A innovation performance and goal orientation. Business: Theory and Practice, 21(2), 555-565.
Published in Issue
Sep 8, 2020
Abstract Views
PDF Downloads
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.


Agarwal, R., & Helfat, C. E. (2009). Strategic renewal of organizations. Organization Science, 20(2), 281–293.

Ahuja, G., & Katila, R. (2001). Technological acquisitions and the innovation performance of acquiring firms: a longitudinal study. Strategic Management Journal, 22(3), 197–220.

Alexander, L., & Knippenberg, D. V. (2014). Teams in pursuit of radical innovation: A goal orientation perspective. Academy of Management Review, 39(4), 423–438.

Baum, J. A. C., Li, X. S., & Usher, J. M. (2000). Making the next move: How experiential and vicarious learning shape the location of chains’ acquisitions. Administrative Science Quarterly, 45(4), 766–801.

Birkinshaw, J., Bresman, H, & Hakanson, L. (2000). Managing the post-acquisition integration process: How the human integration and task integration processes interact to foster value creation. Journal of Management Studies, 37(3), 395–425.

Bobko, P., & Colella, A. (1994). Employee reactions to performance standards: A review and research propositions. Personnel Psychology, 47, 1–29.

Button, S. B., Mathieu, J. E., & Zajac, D. M. (1996). Goal orientation in organizational research: A conceptual and empirical foundation. Organizational Behavior and Human Decision Processes, 67(1), 26–48.

Bower, J. L. (2001). Not M&As are alike: And that matters. In Mergers & acquisitions: A critical reader. Routledge.

Capron, L., & Pistre, N. (2002). When do acquirers earn abnormal returns? Strategic Management Journal, 23(9), 781–794.

Cassiman, B., Colombo, M. G., Garrone, P., & Veugelers, R. (2005). The impact of M&A on the R&D process: An empirical analysis of the role of technological- and market-relatedness. Research Policy, 34(2), 195–220.

Chakrabarti, A., & Mitchell, W. (2013). The persistent effect of geographic distance in acquisition target selection. Organization Science, 24(6), 1805–1826.

Chaudhuri, S., & Tabrizi, B. (1999). Capturing the real value in high-tech acquisitions. Havard Business Review, 77(5), 123–130, 185.

Cohen, F. J. (2005). Macro trends in pharmaceutical innovation. Nature Reviews Drug Discovery, 4, 78–84.

Cohen, W. M., & Levinthal, D. A. (1990). Absorptive capacity: A new perspective on learning and innovation. Administrative Science Quarterly, 35(1), 128–152.

Cloodt, M., Hagedoorn, J., & Kranenburg, H. V. (2006). Mergers and acquisitions: their effect on the innovative performance of companies in high-tech industries. Research Policy, 35(5), 642–654.

Comanor, W. S., & Scherer, F. M. (2013). Mergers and innovation in the pharmaceutical industry. Journal of Health Economics, 32(1), 106–113.

Desyllas, P., & Hughes, A. (2010). Do high technology acquirers become more innovative? Research Policy, 39(8), 1105–1121.

Diener, C. I., & Dweck, C. S. (1978). An analysis of learned helplessness: Continuous changes in performance, strategy, and achievement cognitions following failure. Journal of Personality and Social Psychology, 36, 451–462.

Dikova, D., & Rao Sahib, P. (2013). Is cultural distance a bane or a boon for cross-border acquisition performance? Journal of World Business, 48(1), 77–86.

Dweck, C. S. (1986). Motivational processes affecting learning. American Psychologist, 41(10), 1040–1048.

Eisenhardt, K. M., & Martin, J. A. (2000). Dynamic capabilities: What are they? Strategic Management Journal, 21(10/11), 1105–1121.<1105::AID-SMJ133>3.0.CO;2-E

Farr, J. L., Hofmann, D. A., & Ringenbach, K. L. (1993). Goal orientation and action control theory: Implications for industrial and organizational psychology. International Review of Industrial and Organizational Psychology, 8, 193–232.

Fernald, K. D. S., Pennings, H. P. G., van den Bosch, J. F., Commandeur, H. R., & Classen, E. (2017). The moderating role of absorptive capacity and the differential effects of acquisitions and alliances on Big Pharma firms’ innovation performance. PloS ONE, 12(2), e0172488.

Graebner, M. E. (2004). Momentum and serendipity: How acquired leaders create value in the integration of technology firms. Strategic Management Journal, 25(8/9), 751–777.

Grabowski, H. G., & Kyle, M. (2012). Mergers, acquisitions, and alliances. In P. M. Danzon & S. Nicholson (Eds.), The Oxford handbook of the economics of the biopharmaceutical industry. Oxford University Press.

Graebner, M. E., Eisenhardt, K. M., & Roundy, P. T. (2010). Success and failure in technology acquisitions: Lessons for buyers and sellers. Academy of Management Perspectives, 24(3), 73–92.

Grimpe, C. (2007). Successful product development after firm acquisitions: The role of research and development. The Journal of Product Innovation Management, 24(6), 614–628.

Hagedoorn, J., & Cloodt, M. (2003). Measuring innovative performance: Is there an advantage in using multiple indicators? Research Policy, 32(8), 1365–1379.

Hagedoorn, J., & Sadowski, B. (1999). The transition from strategic technology alliances to mergers and acquisitions: An exploratory study. Journal of Management Studies, 36(1), 87–107.

Hakanson, L. (1995). Learning through acquisitions: Management and integration of foreign R&D laboratories. International Studies of Management and Organization, 25(1–2), 121–157.

Hall, B. H. (2007). Patents and patent policy. Oxford Review of Economic Policy, 23(4), 568–587.

Hamel, G. (2000). Waking up IBM: how a gang of unlikely rebels transformed Big Blue. Harvard Business Review, 78(4), 137–146.

Han, J., Jo, G. S., & Kang, J. (2018). Is high-quality knowledge always beneficial? Knowledge overlap and innovation performance in technological mergers and acquisitions. Journal of Management & Organization, 24(2), 258–278.

Haspeslagh, P. C., & Jemison, D. B. (1991). Managing acquisitions. The Free Press.

Hayward, M. L. A. (2002). When do firms learn from their acquisition experience? Evidence from 1990 to 1995. Strategic Management Journal, 23(1), 21–39.

Higgins, M. J., & Rodriguez, D. (2006). The outsourcing of R&D through acquisitions in the pharmaceutical industry. Journal of Financial Economics, 80(2), 351–383.

Hitt, M. A., Harrison, J. S., & Ireland, R. D. (2001). Mergers & acquisitions: A guide to creating value for stakeholders. Oxford University Press.

Hitt, M. A., Hoskisson, R. E., Johnson, R. A., & Moesel, D. D. (1996). The market for corporate control and firm innovation. Academy of Management Journal, 39(5), 1084 –1119.

Jeon, J., Hong, S., Ohm, J., & Yang, T. (2015). Causal relationships among technology acquisition, absorptive capacity, and innovation performance: evidence from the pharmaceutical industry. Plos One, 10(7), e0131642.

Jo, G. S., Park, G., & Kang, J. (2016). Unravelling the link between technological M&A and innovation performance using the concept of relative absorptive capacity. Asian Journal of Technology Innovation, 24(1), 1–22.

Kaul, A., & Wu, B. (2015). A capabilities-based perspective on target selection in acquisitions. Strategic Management Journal, 37(7), 1220–1239.

Khanna, I. (2012). Drug discovery in pharmaceutical industry: Productivity challenges and trends. Drug Discovery Today, 17(19–20), 1088–1102.

Kim, J. Y., & Finkelstein, S. (2009). The effects of strategic and market complementarity on acquisition performance: Evidence from the US commercial banking industry, 1989–2001. Strategic Management Journal, 30(6), 617–0646.

Laamanen, T., & Keil, T. (2008). Performance of serial acquirers: toward an acquisition program perspective. Strategic Management Journal, 29(6), 633–672.

Lange, S., & Wagner, M. (2019). The influence of exploratory versus exploitative acquisitions on innovation output in the biotechnology industry. Small Business Economics.

Larsson, R., & Finkelstein, S. (1999). Integrating strategic, organizational, and human resource perspectives on mergers and acquisitions: A case survey of synergy realization. Organization Science, 10(1), 1–26.

Lee, Y. J., Shin, K., & Kim, E. (2019). The influence of a firm’s capability and dyadic relationship of the knowledge base on ambidextrous innovation in biopharmaceutical M&As. Sustanability, 11(18), 4920.

Makri, M., Hitt, M. A., & Lane, P. J. (2010). Complementary technologies, knowledge relatedness and invention outcomes in high technology mergers and acquisitions. Strategic Management Journal, 31(6), 602–628.

Malik, N. N. (2009). Biotech acquisitions by big pharma: why and what is next. Drug Discovery Today, 14(17–18), 818–821.

Ocasio, W. (1997). Towards an attention-based view of the firm. Strategic Management Journal, 18, 187–206. <187::AID-SMJ936>3.3.CO;2-B

Ornaghi, C. (2009). Mergers and innovation in big pharma. International Journal of Industrial Organization, 27(1), 70–79.

Pammolli, F., Magazzini, L., & Riccaboni, M. (2011). The productivity crisis in pharmaceutical R&D. Nature Reviews. Drug Discovery, 10(6), 428–438.

Paruchuri, S., Nerkar, A., & Hambrick, D. C. (2006). Acquisition integration and productivity losses in the technical core: Disruption of inventors in acquired companies. Organization Science, 17(5), 545–562.

Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010). How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nature Reviews. Drug Discovery, 9(3), 203–214.

Penner-Hahn, J., & Shaver, J. M. (2005). Does international research and development increase patent output? An analysis of Japanese pharmaceutical firms. Strategic Management Journal, 26(2), 121–140.

Prabhu, J. C., Chandy, R. K., & Ellis, M. E. (2005). The impact of acquisitions on innovation: Poison pill, Placebo, or Tonic? Journal of Marketing, 69, 114–130.

Prahalad, C. K., & Bettis, R. A. (1986). The dominant logic: a new linkage between diversity and performance. Strategic Management Journal, 7(6), 485–501.

Puranam, P., Powell, B. C., & Singh, H. (2006). Due diligence failure as a signal detection problem. Strategic Organization, 4(4), 319–348.

Puranam, P., & Srikanth, K. (2007). What they know vs. what they do: How acquirers leverage technology acquisitions. Strategic Management Journal, 28(8), 805–825.

Ranft, A. L., & Lord, M. D. (2000). Acquiring new knowledge: The role of retaining human capital in acquisitions of high-tech firms. The Journal of High Technology Management Research, 11(2), 295–319.

Ravenscraft, D. J., & Scherer, F. M. (1987). Life after takeover. The Journal of Industrial Economics, 36(2), 147–156.

Ringel, M. S., & Choy, M. K. (2017). Do large mergers increase or decrease the productivity of pharmaceutical R&D? Drug Discovery Today, 22(12), 1749–1753.

Ruckman, K. (2009). Technology sourcing acquisitions: What they mean for innovation potential. Journal of Strategy and Management, 2(1), 56–75.

Santos, F., & Eisenhardt, K. M. (2009). Constructing markets and shaping boundaries: Entrepreneurial power in nascent fields. Academy of Management Journal, 52(4), 643–671.

Schildt, H. A., & Laamanen, T. (2006). Who buys whom: Information environments and organizational boundary spanning through acquisitions. Strategic Organization, 4(2), 111–113.

Schweizer, L. (2005). Knowledge transfer and R&D in pharmaceutical companies: A case study. Journal of Engineering and Technology Management, 22(4), 315–331.

Shelton, L. M. (1988). Strategic business fits and corporate acquisition: Empirical evidence. Strategic Management Journal, 9(3), 279–287.

Shibayama, S., Tanikawa, K., Fujimoto, R., & Kimura, H. (2008). Effect of mergers and acquisitions on drug discovery: perspective from a case study of a Japanese pharmaceutical company. Drug Discovery Today, 13(1–2), 86–93.

Shrivastava, P. (1986). Post-merger integration. Journal of Business Strategy, 7(1), 65–76.

Song, C. H., & Leker, J. (2018). Differentiation of innovation strategies based on pharmaceutical licensing agreements: Insight from Korean pharmaceutical firms. Technology Analysis & Strategic Management, 31(2), 169–185.

Trautwein, F. (1990). Merger motives and merger prescriptions. Strategic Management Journal, 11(4), 283–295.

Vaara, E., Sarala, R., Stahl, G. K., & Björkman, I. (2012). The impact of organizational and national cultural differences on social conflict and knowledge transfer in international acquisitions. Journal of Management Studies, 49(1), 1–27.

VandeWalle, D., Cron, W. L., & Slocum, J. W. Jr. (2001). The role of goal orientation following performance feedback. Journal of Applied Psychology, 86(4), 629–640.

Yu, J., Engleman, R. M., & Van de Ven, A. H. (2005). The integration journey: An attention-based view of the merger and acquisition integration process. Organization Studies, 26(10), 1501–1528.

Zhao, X., Lin, D., & Hao, T. (2019). A new discussion on the relationship between M&A and innovation in an emerging market: the moderating effect of post-acquisitions R&D investment. Technology Analysis & Strategic Management, 31(12), 1447–1461.